Thrombospondin 1 expression and angiogenesis in breast carcinoma and their relation with platelet activity

Upsala Journal of Medical Sciences

Volumn 114, Issue 2, 2009, Pages 108-115

  Tokyol, Cigdem ^a   Ersoz, Gulriz ^b   Dilek, Fatma Husniye ^a   Gencer, Ercan ^b   Kosar, Mehmet Nuri ^a   Dilek, Osman Nuri ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Breast carcinoma; Platelet; Platelet activity; Thrombospondin

Indexed keywords

CYCLIC GMP; THROMBOSPONDIN 1;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; CYTOLOGY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; THROMBOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIC GMP; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1;

EID: 67650596838     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009730902761797     Document Type: Article

References (45)

1. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003. p. 13-60.
2. Elston CW, Ellis IO. Classification of malignant breast disease. In: Elston CW, Ellis IO, editors. The breast, systemic pathology, 3rd edn. Edinburgh: Churchill Livingstone, 1998. p. 239-247.
3. Tavassoli FA. General considerations. In: Tavassoli FA, editor. Pathology of the breast, 2nd edn. Hong Kong: Appleton and Lange; 1999. p. 27-74.
4. Kumar V, Abbas AK, Fausto N. Tissue Renewal and Repair: Regeneration, Healing, and Fibrosis. In: Kumar V, Abbas AK, Fausto N, editors Robbins Pathologic Basis of Disease, 7th edn. China: Elsevier Saunders, 2005. p. 87-118.
5. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58:1298-1304.
6. Grant SW, Kysthoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev. 1998;22: 185-194.
7. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, et al. Enhanced expression of thrombospondin- 1 and hypovascularity in human cholangiocarcinoma. Hepatology. 1998;28:1512-1517.
8. Volm M, Koomagi R, Mattern J. Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an immunohistochemical study of 28 cases. Anticancer Res. 1999;19:333-336.
9. Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, et al. Angiogenic characteristics of circulating and tumoral thrombospondin-1 in breast cancer. Int J Oncol. 2007;31:1127-1132.
10. Packham MA, Mustard JF. Platelet adhesion. Prog Hemos Thromb. 1984;7:211-288.
11. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood. 1984;63:55-63.
12. Ersöz G, Yakaryilmaz A, Zergero(lu AM. The effect of acute submaximal exercise on platelet aggregation in different menstruel phases in women. Thromb Res. 2003;108:147-50.
13. Brune B, Ullrich V. Different calcium pools in human platelets and their role in thromboxane A2 formation. J Biol Chem. 1991;266:19232-19237.
14. Pistono M, Bergerone S, Carrieri L, Paglia I, Stefano D, Caprizzi A, et al. Platelet cyclic GMP levels in unstable angina and myocardial infarction. Platelets. 2002;13:307-311.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
16. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastases- correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
17. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol. 1992;23:755-761.
18. Battifora H, Mehta P, Ahn C, Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunohistochem. 1993;1: 39-45.
19. Folkman JJ. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
20. Valentino LA, Ladisch S. Circulating tumour gangliosides enhance platelet activation. Blood. 1994;83:2872-2877.
21. Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ. Prognostic significance of platelet and microvessel counts in operabl non-small cell lung cancer. Lung Cancer. 2000;29:169-177.
22. Pedersen LM, Milman N. Prognostic significance of thyrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9:1826-1830. (Pubitemid 26294751)
23. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998;70:210-214.
24. O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL. Vascular endothelial growth factor, platelet counts, and prognosis in renal cancer. Lancet. 1999;353:1494-1495.
25. Pinedo HM, Verheul HMW, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 1998;352:1775-1777.
26. Jurasz P, Alonso-Escolano D, Rodomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cellinduced platelet aggregation. Br J Pharmacol. 2002;143: 819-826.
27. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. 1995;57: 707-736.
28. Dishy V, Harris PA, Pierce R, Prasad HC, Sowowara G, Boner HL, et al. Sildenafil does not improve nitric oxidemediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol. 2003;57:209-212.
29. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 1987;39:163-196.
30. Di Nicola M, Santoleri F, Soscia S, Fioroni M, Rubini C, Piattelli A, et al. Cyclic guanosine monophosphate role in human carcinoma pathogenesis. Nucleosides Nucleotides Nucleic Acids. 2004;23:1555-1558.
31. Israeli E, Raz B, Kerner H, Barzilai D. Cyclic nucleotide levels in human breast cancer and in rat mammary tissues during tumour development. Breast Cancer Res Treat. 1985;6:241-248.
32. Chaimoff C, Malachi T, Halbrecht I. Prostaglandin E2 and cyclic nucleotides in plasma and urine of colonic cancer patients. J Cancer Res Clin Oncol. 1985;110:153-156.
33. Gallo O, Sardi I, Masini M, Franchi A. Re: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999;91:1509-1511.
34. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin-1. J Cell Biol. 1995;130:503-506.
35. Bornstein P, Stage EH. Thrombospondins. Methods Enzymol. 1994;245:62-85.
36. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties of a thrombin sensitive protein of human platelets. J Biol Chem. 1972;247:2723-2731.
37. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, et al. Thrombospondin levels in patients with malignancy. Thromb Haemost. 1992;67:607-611.
38. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T, Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer. 1998;82:632-638.
39. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR, et al. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer. 1994;73:2853-2858.
40. Amenta PS, Martinez-Hernandez A, Trelstad RL. Repair and regeneration. In: Damjanov I, Linder J, editors. Anderson's pathology, vol.2, 10th edn. St. Louis: Mosby, 1996. p. 416-447.
41. Tuszynski GP, Kowalska MA, Karczewski J, Eichen J, Rothman VL, Capuzzi DM. Thrombospondin and VLDL promote platelet adhesion--evidence for a common platelet adhesion receptor. Thromb Haemostas. 1989;62:418.
42. Tuszynski GP, Rothman VL, Murphy A, Siegler K, Knudsen KA. Thrombospondin promotes platelet aggregation. Blood. 1988;72:109-115.
43. Wong SY, Purdie AT, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. Am J Pathol. 1992;140:1473-1482.
44. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD. Expression of Thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. 1993;53:1421-1430.
45. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 2003;5:R136-43.